Eli Lilly and Company (LLY)vsZEN Graphene Solutions Ltd (ZTEK)
LLY
Eli Lilly and Company
$934.60
+9.80%
HEALTHCARE · Cap: $760.43B
ZTEK
ZEN Graphene Solutions Ltd
$0.43
+0.78%
HEALTHCARE · Cap: $48.29M
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 6912657% more annual revenue ($65.18B vs $942,880). LLY leads profitability with a 31.7% profit margin vs 0.0%. LLY earns a higher WallStSmart Score of 78/100 (B+).
LLY
Strong Buy78
out of 100
Grade: B+
ZTEK
Avoid23
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for LLY.
Margin of Safety
+89.6%
Fair Value
$6.28
Current Price
$0.43
$5.85 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 101 in profit
Keeps 32 of every $100 in revenue as profit
Strong operational efficiency at 44.9%
Revenue surging 42.6% year-over-year
Earnings expanding 51.4% YoY
Revenue surging 73.1% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
Premium valuation, high expectations priced in
Elevated debt levels
Trading at 31.5x book value
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
ROE of -56.6% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 31.7% and operating margin at 44.9%. Revenue growth of 42.6% demonstrates continued momentum.
Bull Case : ZTEK
The strongest argument for ZTEK centers on Revenue Growth, Debt/Equity. Revenue growth of 73.1% demonstrates continued momentum.
Bear Case : LLY
The primary concerns for LLY are P/E Ratio, Debt/Equity, Price/Book. Debt-to-equity of 1.60 is elevated, increasing financial risk.
Bear Case : ZTEK
The primary concerns for ZTEK are EPS Growth, Market Cap, Profit Margin.
Key Dynamics to Monitor
LLY profiles as a growth stock while ZTEK is a hypergrowth play — different risk/reward profiles.
LLY carries more volatility with a beta of 0.50 — expect wider price swings.
ZTEK is growing revenue faster at 73.1% — sustainability is the question.
LLY generates stronger free cash flow (678M), providing more financial flexibility.
Bottom Line
LLY scores higher overall (78/100 vs 23/100), backed by strong 31.7% margins and 42.6% revenue growth. ZTEK offers better value entry with a 89.6% margin of safety. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →ZEN Graphene Solutions Ltd
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
ZEN Graphene Solutions Ltd (ZTEK) is at the forefront of materials technology, specializing in the development and commercialization of high-purity graphene products derived from natural graphite. By leveraging proprietary extraction techniques, ZTEK aims to transform diverse sectors, including environmental remediation, energy storage, and advanced manufacturing, with its graphene-based solutions. The company's strong emphasis on sustainability, paired with ongoing research and development initiatives, positions it as a leader in the graphene technology market. As ZTEK exploits growth opportunities and drives innovation, it is poised to enhance long-term shareholder value amid a growing global demand for advanced materials.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?